|

Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects.

RECRUITINGN/ASponsored by BioLab Holdings
Actively Recruiting
PhaseN/A
SponsorBioLab Holdings
Started2026-09-18
Est. completion2028-07-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

A multicenter, prospective, randomized controlled clinical trial assessing the efficacy of a novel cellular, acellular, matrix-like product (CAMP) plus standard of care versus standard of care alone in the management of post-mohs micrographic surgery defects.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* The potential subject must be at least 18 years of age or older.
* The potential subject must have undergone Mohs micrographic surgery for a cutaneous malignancy (e.g., basal cell carcinoma, or squamous cell carcinoma).
* The potential subject must have a post-Mohs surgical defect that is suitable for treatment with a CAMP product or healing by secondary intention.
* The surgical site has received standard Mohs excision and hemostasis with no requirement for immediate flap or graft reconstruction as determined by the treating surgeon.
* If the surgical defect is on the lower extremity, the limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:

  1. Ankle-Brachial Index (ABI) between 0.7 and ≤ 1.3;
  2. Toe-Brachial Index (TBI) ≥ 0.6;
  3. Transcutaneous Oxygen Measurement (TCOM) ≥ 40 mmHg;
  4. Pulse Volume Recording (PVR): biphasic.
* If the subject has multiple Mohs defects, they must be separated by at least 2 cm. The largest defect satisfying the inclusion and exclusion criteria will be designated as the target wound.
* The potential subject must agree to attend the weekly study visits required by the protocol.
* The potential subject must be willing and able to participate in the informed consent process.

Exclusion Criteria:

* The potential subject is known to have a life expectancy of \< 6 months.
* The potential subject's target wound is not secondary to a Mohs excision.
* The target wound is infected or there is cellulitis in the surrounding skin.
* The target wound:

  1. Exposes tendon, bone, or joint space, and/or
  2. Requires immediate complex flap or graft reconstruction in the judgment of the surgeon.
* The potential subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
* The potential subject has glycated hemoglobin (HbA1c) greater than 10% within 3 months of the initial screening visit.
* The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.

Conditions4

CancerCutaneous MalignancyMohs Micrographic SurgeryMohs Surgical Defect

Locations1 site

Southside Dermatology Mohs and Skin Surgery
Tulsa, Oklahoma, 74132
Ana Montalva(918) 760-0700amontalva@dermatologyok.com

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.